---
title: "Tigermed Says Probe Into Major Shareholders Will Not Hit Operations"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286261011.md"
description: "Hangzhou Tigermed Consulting Co., Ltd. clarified that an ongoing regulatory investigation into its major shareholders' historical equity disclosures will not impact its business operations. The company reassured shareholders and potential investors to rely on official announcements for information and to exercise caution in trading. The latest analyst rating for Tigermed's stock (HK:3347) is a Buy, with a price target of HK$55.00. The company specializes in providing services to the pharmaceutical and life sciences sectors."
datetime: "2026-05-13T12:11:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286261011.md)
  - [en](https://longbridge.com/en/news/286261011.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286261011.md)
---

# Tigermed Says Probe Into Major Shareholders Will Not Hit Operations

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Hangzhou Tigermed Consulting Co., Ltd. Class H ( (HK:3347) ) just unveiled an update.

Hangzhou Tigermed Consulting has issued a clarification following market speculation about whether its controlling shareholders, chairman Ye Xiaoping and director Cao Xiaochun, complied with disclosure rules on past shareholding changes. The company stresses that these matters concern historical equity change disclosures by the two individuals, which it says were publicly announced through prior reduction notices, periodic reports and a brief equity change report.

The company emphasizes that the ongoing regulatory investigation into these historical disclosures does not relate to its underlying business operations and will not affect its normal activities. It also urges shareholders and potential investors to rely solely on official company announcements for information on the group and to exercise caution when trading its shares amid the current scrutiny.

The most recent analyst rating on (HK:3347) stock is a Buy with a HK$55.00 price target. To see the full list of analyst forecasts on Hangzhou Tigermed Consulting Co., Ltd. Class H stock, see the HK:3347 Stock Forecast page.

**More about Hangzhou Tigermed Consulting Co., Ltd. Class H**

Hangzhou Tigermed Consulting Co., Ltd. is a China-incorporated company listed in Hong Kong and operates through a group structure. It provides professional services to the pharmaceutical and life sciences sectors, positioning itself as a key player in contract research and related consulting for clinical development. The company serves both domestic and international clients through regulated capital market disclosures.

**Average Trading Volume:** 1,634,388

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$44.48B

For a thorough assessment of 3347 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [03347.HK](https://longbridge.com/en/quote/03347.HK.md)
- [300347.CN](https://longbridge.com/en/quote/300347.CN.md)

## Related News & Research

- [Hangzhou Tigermed Unveils Up to RMB1 Billion A-Share Buyback Plan](https://longbridge.com/en/news/286280793.md)
- [Hangzhou Tigermed issues unaudited 2026 first-quarter report](https://longbridge.com/en/news/284352795.md)
- [Should You Be Adding Daewoong Pharmaceutical (KRX:069620) To Your Watchlist Today?](https://longbridge.com/en/news/286824214.md)
- [16:52 ETNexusTek Named a Contender in ISG Provider Lens® Life Sciences Digital Services 2026 Report](https://longbridge.com/en/news/286818120.md)
- [Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1 | WVE Stock News](https://longbridge.com/en/news/286925108.md)